CA2018563A1 - N-heteroaryl-purin-6-amines, procede de preparation et utilisation comme medicaments - Google Patents

N-heteroaryl-purin-6-amines, procede de preparation et utilisation comme medicaments

Info

Publication number
CA2018563A1
CA2018563A1 CA2018563A CA2018563A CA2018563A1 CA 2018563 A1 CA2018563 A1 CA 2018563A1 CA 2018563 A CA2018563 A CA 2018563A CA 2018563 A CA2018563 A CA 2018563A CA 2018563 A1 CA2018563 A1 CA 2018563A1
Authority
CA
Canada
Prior art keywords
lower alkyl
aryl
purin
heteroaryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2018563A
Other languages
English (en)
Other versions
CA2018563C (fr
Inventor
Richard Charles Effland
Joseph Thomas Klein
Larry Davis
Gordon Edward Olsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Hoechst Roussel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharmaceuticals Inc filed Critical Hoechst Roussel Pharmaceuticals Inc
Publication of CA2018563A1 publication Critical patent/CA2018563A1/fr
Application granted granted Critical
Publication of CA2018563C publication Critical patent/CA2018563C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Television Signal Processing For Recording (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
CA002018563A 1989-06-09 1990-06-08 N-heteroaryl-purin-6-amines, procede de preparation et utilisation comme medicaments Expired - Fee Related CA2018563C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US363,837 1989-06-09
US07/363,837 US5017578A (en) 1989-06-09 1989-06-09 N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents

Publications (2)

Publication Number Publication Date
CA2018563A1 true CA2018563A1 (fr) 1990-12-09
CA2018563C CA2018563C (fr) 2000-09-19

Family

ID=23431950

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002018563A Expired - Fee Related CA2018563C (fr) 1989-06-09 1990-06-08 N-heteroaryl-purin-6-amines, procede de preparation et utilisation comme medicaments

Country Status (21)

Country Link
US (1) US5017578A (fr)
EP (1) EP0402752B1 (fr)
JP (1) JPH06102663B2 (fr)
KR (2) KR100199524B1 (fr)
CN (1) CN1029968C (fr)
AT (1) ATE127807T1 (fr)
AU (1) AU636351B2 (fr)
CA (1) CA2018563C (fr)
DE (1) DE69022294T2 (fr)
DK (1) DK0402752T3 (fr)
ES (1) ES2078267T3 (fr)
FI (1) FI902850A7 (fr)
GR (1) GR3017743T3 (fr)
HU (1) HU207320B (fr)
IE (1) IE68433B1 (fr)
IL (1) IL94665A (fr)
MX (1) MX21088A (fr)
NO (1) NO902555L (fr)
NZ (1) NZ233970A (fr)
PT (1) PT94297B (fr)
ZA (1) ZA904443B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432164A (en) * 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
US5319096A (en) * 1992-04-03 1994-06-07 Hoechst-Roussel Pharmaceuticals Inc. (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
JP3355237B2 (ja) * 1993-10-15 2002-12-09 呉羽化学工業株式会社 Ｎ−（置換アミノ）ピロール誘導体、その製造方法及び除草剤
FI964468A0 (fi) * 1994-05-10 1996-11-06 Sandoz Ltd Adenosiinijohdannaisia
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
RU2172320C2 (ru) * 1996-08-27 2001-08-20 Си Ви Терапьютикс, Инк. Производные аденозина, фармацевтическая композиция и способ коррекции электрических нарушений в сердце млекопитающего
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
MXPA06001758A (es) * 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
CN100447143C (zh) * 2003-08-15 2008-12-31 Irm责任有限公司 作为rtk抑制剂的6-取代的苯胺基嘌呤
CN102379684B (zh) 2005-04-28 2014-11-19 普罗透斯数字保健公司 药物信息系统
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
EP2398500B1 (fr) 2009-02-20 2019-03-13 2-BBB Medicines B.V. Sustème d'administration de médicament à base de glutathionne
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CN104744470A (zh) * 2014-10-31 2015-07-01 合肥平光制药有限公司 一种茶碱的合成方法
WO2017160922A1 (fr) 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Composés analgésiques
CN106632339B (zh) * 2016-12-16 2018-11-27 温州医科大学 一种6-取代-9h-嘌呤类衍生物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016378A (en) * 1959-07-01 1962-01-09 Thomae Gmbh Dr K Amino-substituted purine derivatives
BE768925A (fr) * 1970-06-30 1971-11-03 Takeda Chemical Industries Ltd Derives d'adenosine et procede de preparation
JPS4935635B1 (fr) * 1970-12-28 1974-09-25
US3936454A (en) * 1973-08-14 1976-02-03 Warner-Lambert Company 5-Amino-4-chloro-6-(substituted amino)-pyrimidines
US3862189A (en) * 1973-08-14 1975-01-21 Warner Lambert Co Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents
JPS57171998A (en) * 1981-04-15 1982-10-22 Fujisawa Pharmaceut Co Ltd Adenosine derivative and its salt, preparation thereof and medicinal composition containing the same
US4514405A (en) * 1981-09-17 1985-04-30 Merck Patent Gesellschaft Mit Beschrankter Haftung Use of adenosine derivatives as anticonvulsants
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
AU582359B2 (en) * 1984-04-18 1989-03-23 Nelson Research & Development Company N-6 substituted adenosine derivatives as cardiac vasodilators
US4657897A (en) * 1984-06-22 1987-04-14 Warner-Lambert Company N6 -substituted adenosines for treating pain
CA1254888A (fr) * 1984-10-26 1989-05-30 Bharat Trivedi N.sup.6-bicyclo-adenosines
US4752610A (en) * 1985-12-04 1988-06-21 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-1-yl)pyridinamines having memory enhancing properties
US4780452A (en) * 1986-09-08 1988-10-25 Burroughs Wellcome Co. F-substituted-3-β-D-ribofuranosyl-3H-imidazo[4,5-b]pyridines and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
KR100210179B1 (ko) 1999-07-15
HUT54156A (en) 1991-01-28
FI902850A7 (fi) 1990-12-10
PT94297A (pt) 1991-02-08
DK0402752T3 (da) 1996-01-15
NO902555D0 (no) 1990-06-08
ES2078267T3 (es) 1995-12-16
HU207320B (en) 1993-03-29
IL94665A0 (en) 1991-04-15
KR100199524B1 (ko) 1999-06-15
KR910000730A (ko) 1991-01-30
HU903768D0 (en) 1990-11-28
FI902850A0 (fi) 1990-06-07
EP0402752A1 (fr) 1990-12-19
AU636351B2 (en) 1993-04-29
CN1029968C (zh) 1995-10-11
PT94297B (pt) 1997-01-31
IE902077L (en) 1990-12-09
ZA904443B (en) 1991-03-27
CN1047866A (zh) 1990-12-19
ATE127807T1 (de) 1995-09-15
JPH06102663B2 (ja) 1994-12-14
US5017578A (en) 1991-05-21
NZ233970A (en) 1993-02-25
NO902555L (no) 1990-12-10
DE69022294T2 (de) 1996-03-14
DE69022294D1 (de) 1995-10-19
IL94665A (en) 1994-06-24
IE68433B1 (en) 1996-06-12
MX21088A (es) 1993-11-01
GR3017743T3 (en) 1996-01-31
AU5691990A (en) 1990-12-13
CA2018563C (fr) 2000-09-19
EP0402752B1 (fr) 1995-09-13
JPH0324080A (ja) 1991-02-01

Similar Documents

Publication Publication Date Title
CA2024572A1 (fr) 4-pyrimidinamines et pyrimidinediamines substituees en n, procede depreparation et utilisation comme medicaments
AU636351B2 (en) N-heteroaryl-purin-6-amines, a process for their preparation and their use as medicaments
CA2029265A1 (fr) Derives 4- et 6-carbamate de physostigmine; methode et produits intermediaires pour leur preparation, leur utilisation comme medicaments
NO874350D0 (no) Fremgangsmaate for fremstilling av antibakterielle forbindelser.
CA2031079A1 (fr) Aminocarbonylcarbamates apparentes a la physostigmine, un procede pour les preparer et leur utilisation comme medicaments
CA2013087A1 (fr) Derives de carbonate d'eseroline, procede de preparation et utilisation comme medicaments
CA2128202A1 (fr) Derives alkyles de la trazodone agissant sur le snc
CA2050875A1 (fr) 3-(1h-indazol-3-yl)-4-pyridinamines, methode et intermediaires utilises pour leur preparation et leur emploi comme medicaments
GR3017280T3 (en) Aminoalkylchromones, process for their preparation and compositions containing them.
CA2040489A1 (fr) 4-¬3-(4-oxothiazoldinyl)|butynylamines, procede de preparation et utilisation comme medicaments

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed